Servet joins Jiménez Schuhmacher's viral challenge to make metastatic breast cancer visible
8 March, 2021
A patient with metastatic breast cancer: «When you are diagnosed, they give you five years to live. "I want to break statistics"
8 March, 2021
In some asymptomatic cases, or with very mild symptoms, the body reacts naturally and quickly to the coronavirus, and does not allow the formation of specific antibodies.
Not all people who have had Covid-19 develop sufficient antibodies to protect them against the virus, according to doctors and specialists from VithasLab, who warn that the determination of antibodies depends on whether they were acquired after the disease or after vaccination. .
"In some asymptomatic cases, or with very mild symptoms, the body reacts naturally and very quickly to the presence of the SARS-CoV-2 coronavirus, which causes covid-19. This rapid response has a negative aspect in the long run. term, since, by combating the infection early, it does not allow the formation of specific antibodies and, therefore, does not generate immunity," said the head of the VithasLab laboratory in Valencia, Vicenta Sanhermelando Rossi.
For this reason, he has highlighted the importance of people who have had Covid undergoing an antibody determination test. One of the most effective methods for this is the serological determination of IgG with the 'ELISA' method, an immunoassay that quantifies the amount of existing antibodies in vitro.
Long-term immunization
Thus, a quantity equal to or greater than 15 means that there is protection against future contacts with the coronavirus. The duration of this protection is not yet defined, since not enough time has passed to be able to determine it, but, as Sanhermelando has indicated, there is scientific consensus that "immunity persists beyond eight months after" the generation of these antibodies.
Furthermore, the head of the VithasLab laboratory in Valencia has highlighted that the antibodies acquired after the disease are different from those generated after vaccination, explaining that the antibodies that confer protection against future SARS-CoV-2 infections, such as before Other viruses are called 'neutralizing bacteria'.
Thus, the antibodies that are generated during the disease are immunoglobulins against various antigens of the virus and not all of them are neutralizing. In fact, it has not yet been confirmed whether all patients generate these 'ac' antibodies, nor whether their levels are sufficient to provide protection. In addition, there is a percentage of patients, estimated to be between 10% and 30% of cases, in which the amount of antibodies is not detectable.
Finally, the expert has reported that vaccination generates exclusively 'neutralizing ac' type antibodies, and does so at levels more than sufficient to ensure immunization against future exposure to the coronavirus.
